



**HAL**  
open science

## Editorial: PCOS: from infertility to pregnancy.

Stefano Palomba, Didier Dewailly

► **To cite this version:**

Stefano Palomba, Didier Dewailly. Editorial: PCOS: from infertility to pregnancy.. *Frontiers in Endocrinology*, 2023, *Frontiers in Endocrinology*, 14, pp.1220014. 10.3389/fendo.2023.1220014. hal-04677455

**HAL Id: hal-04677455**

**<https://hal.univ-lille.fr/hal-04677455v1>**

Submitted on 26 Aug 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



## OPEN ACCESS

EDITED AND REVIEWED BY

Richard Ivell,  
University of Nottingham, United Kingdom

\*CORRESPONDENCE

Stefano Palomba

✉ Prof.Stefano.Palomba@gmail.com

RECEIVED 09 May 2023

ACCEPTED 17 May 2023

PUBLISHED 30 May 2023

## CITATION

Palomba S and Dewailly D (2023) Editorial:  
PCOS: from infertility to pregnancy.  
*Front. Endocrinol.* 14:1220014.  
doi: 10.3389/fendo.2023.1220014

## COPYRIGHT

© 2023 Palomba and Dewailly. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Editorial: PCOS: from infertility to pregnancy

Stefano Palomba<sup>1\*</sup> and Didier Dewailly<sup>2</sup><sup>1</sup>Sapienza University of Rome, Rome, Italy, <sup>2</sup>Université de Lille, Nord-Pas-de-Calais, France

## KEYWORDS

cardiovascular risk, infertility, PCOS, polycystic ovarian syndrome, pregnancy, reproduction

## Editorial on the Research Topic

## PCOS: from infertility to pregnancy

Polycystic ovary syndrome (PCOS) is a heterogeneous and very frequent endocrinological disease associated with reproductive alterations (1). Women with PCOS have reduced fertility in the presence of ovulatory dysfunction that is a key element in the pathogenesis of PCOS (2). However, patients with PCOS have alterations in several reproductive pathways independently of their ovulatory status (3). These include primary and secondary alterations of the oocyte and embryo quality (4), and of endometrial competence (5). Those endometrial alterations, with subsequent abnormal trophoblast invasion and placentation, are probably the main etiologic factor of the increased incidence of pregnancy complications in PCOS (6). However, PCOS is also associated with an increased cardiometabolic risk (1), albeit clinical evidence about the related mortality is still lacking.

The current Research Topic includes 11 papers, selected after an intense reviewing process. Five articles represent original research, whereas the other 6 consisted of narrative and systematic reviews with or without meta-analysis.

In an experimental animal study, [Feng et al.](#) assessed the therapeutic effect and mechanism of action of *Dendrobium officinale* extract, which is commonly administered in China as a dietary supplement, in letrozole-induced PCOS rats. *Dendrobium officinale* extract reduced body weight, and restored estrous cycle by improving follicle development and lowering testosterone levels. These effects were potentially mediated by gut microbiota changes. [Shen et al.](#) assessed the effect of curcumin, a phenolic compound with potent anti-inflammatory and antioxidant properties also administered as a dietary supplement. The meta-analysis of 7 randomized controlled trials (RCTs) demonstrated that curcumin is safe and effective to reduce body weight, to improve inflammation, and markers of insulin resistance and lipid profile. Unfortunately, many trials had a high risk of bias, are from the Asiatic area and included a very low number of randomized subjects. Similarly, [Rong et al.](#) reported the synthesis of data from 16 RCTs for a total of 1385 patients showing the safety and efficacy of the *Guizhi fuling* pill as an adjuvant treatment for infertile patients with PCOS. When added to Western medicine, including oral contraceptives, insulin-sensitizing drugs, and clomiphene citrate, *Guizhi fuling* pill, a traditional Chinese herbal formula, induced a significant improvement in the ovulation and pregnancy rates of about 24% and 53%, respectively, in PCOS patients. Again the suboptimal certainty of evidence and the unclear risk of bias precluded any clear-cut recommendation for clinicians. A narrative

review by [Shawky](#) discussed the available experimental and clinical data on the increased cardio-metabolic risk in offspring of women with PCOS exploring the different theories supporting that risk and analyzing the sex differences. Clearly, the increased cardiometabolic risk in offspring of mothers with PCOS probably needs the interaction of environmental (not only prenatal but also postnatal) and genetic factors over the lifespan. A sex interaction cannot be excluded as mediator of cardiometabolic outcomes. [Gao et al.](#) firstly performed a systematic review with meta-analysis, including 18 studies (case-control and cohort studies) for a total of 1265 PCOS patients and 894 controls. These studies aimed to evaluate the potential role of apelin and chemerin, two newly identified adipokines widely expressed in different organs. The data synthesis demonstrates that only chemerin, but not apelin, is significantly higher in PCOS patients suggesting that chemerin may be a therapeutic target to reduce the cardiovascular risk in patients with PCOS. Acupuncture is more and more used as a complementary and alternative treatment for infertility with controversial data regarding its efficacy (7). A comprehensive systematic review by [Ye et al.](#) on the use of acupuncture in women with PCOS underlined that all available meta-analyses agree that clinical evidence about the effectiveness of acupuncture for improving fertility is scarce in PCOS patients. Therefore, robust and well-designed clinical trials are needed to confirm or refute these hypotheses of efficacy. In the current Research Topic, the effect of acupuncture in PCOS patients under metformin administration was tested by [Chen et al.](#) in a systematic review with meta-analysis of 9 RCTs including a total of 1159 women. Even if acupuncture improved the ovulation and pregnancy rate by about 30% in PCOS patients with a potential action on the insulin resistance, the risk of bias was high for many studies and the quality of the evidence was defined as low to very low (8). Another interesting RCT by [Zhang et al.](#) assessed the effect of canagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, a novel class of hypoglycemic oral drugs that enhance the renal glucose loss in 51 women with PCOS. Three months of canagliflozin administration induced only a significant, but clinically modest, beneficial effect on total testosterone and glucose concentrations.

Surprisingly, only one paper was published in this Research Topic about evidence-based treatment for infertile PCOS patients, such as letrozole administration (9, 10). The retrospective analysis by [Shi et al.](#) on a total of 539 infertile patients with PCOS, showed that letrozole administered starting on day 5 following menstrual bleeding is associated with a cumulative conception rate about 10% higher in comparison with administration on day 3 due to a potentially better endometrial thickness.

During the last years, the follicular output rate (FORT) has acquired a progressively more important role for scientists and clinicians as a marker of good reproductive prognosis. FORT is the ratio of pre-ovulatory follicle count on the trigger day to the antral follicle count (AFC), and is considered an important criterion by which to quantify the follicular development potential (11). [Jiang et al.](#) retrospectively analyzed the effects of FORT on reproductive performance in 454 infertile patients with PCOS scheduled for IVF cycles and showed that FORT is directly related to the cumulative pregnancy and live birth rates

when the FORT was less than 70%. After stratification analyses, each additional unit of FORT increased the cumulative live birth rate by 1.3% confirming that FORT may be used as a simple and non-invasive tool to assess the dynamic changes of follicular growth in response to exogenous gonadotropins in the clinical practice.

Finally, in the current Research Topic, [Bibi et al.](#) published for the first time a link between some specific mitochondrial DNA mutations and PCOS using next-generation sequencing (NGS). Six regions with common variations in all analyzed genomes were identified, even if individual variations were also reported. Interestingly, the score-based pathogenicity analysis of mitochondrial variants that demonstrated frameshift mutations in the ND2 gene was associated to the highest risk for PCOS, potentially opening the door to predisposition tests for PCOS.

In conclusion, the reading of the current Research Topic, beside the scientific value of the specific papers published, arouse in us two main considerations. First, very few conclusions may be drawn from systematic reviews after considering the suboptimal quality of many of the studies available. Second, there is great interest from Asian scientists in regard to PCOS and its management in conjunction with alternative and adjuvant treatments. We hope that this Research Topic may stimulate the design of well-structured and powered RCTs, also in Western countries, to confirm or refute these new, interesting, and potentially useful strategies of treatment for women with PCOS.

## Author contributions

SP and DD conceptualized the study, acquired the main data, drafted the article, provided their final approval of the version to be published and agree to be accountable for all aspects of the work especially regarding its accuracy and integrity.

## Acknowledgments

We thank all Authors who contributed to this Research Topic

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## References

1. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. *Endocr Rev* (2015) 36:487–525. doi: 10.1210/er.2015-1018
2. Dewailly D, Robin G, Peigne M, Decanter C, Pigny P, Catteau-Jonard S. Interactions between androgens, FSH, anti-müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary. *Hum Reprod Update* (2016) 22:709–24. doi: 10.1093/humupd/dmw027
3. Palomba S. Is fertility reduced in ovulatory women with polycystic ovary syndrome? *Opin Pap Hum Reprod* (2021) 36:2421–8. doi: 10.1093/humrep/deab181
4. Palomba S, Daolio J, La Sala GB. Oocyte competence in women with polycystic ovary syndrome. *Trends Endocrinol Metab* (2017) 28:186–98. doi: 10.1016/j.tem.2016.11.008
5. Palomba S, Piltonen TT, Giudice LC. Endometrial function in women with polycystic ovary syndrome: a comprehensive review. *Hum Reprod Update* (2021) 27:584–618. doi: 10.1093/humupd/dmaa051
6. Palomba S, de Wilde MA, Falbo A, Koster MP, La Sala GB, Fauser BC. Pregnancy complications in women with polycystic ovary syndrome. *Hum Reprod Update* (2015) 21:575–92. doi: 10.1093/humupd/dmv029
7. Wu XK, Stener-Victorin E, Kuang HY, Ma HL, Gao JS, Xie LZ. Effect of acupuncture and clomiphene in Chinese women with polycystic ovary syndrome: a randomized clinical trial. *JAMA* (2017) 317:2502–14. doi: 10.1001/jama.2017.7217
8. Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. *Endocr Rev* (2009) 30:1–50. doi: 10.1210/er.2008-0030
9. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Hum Reprod* (2018) 33:1602–18. doi: 10.1093/humrep/dey256
10. Wang R, Li W, Bordewijk EM, Legro RS, Zhang H, Wu X, et al. First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis. *Hum Reprod Update* (2019) 25:717–32. doi: 10.1093/humupd/dmz029
11. Genro VK, Grynberg M, Scheffer JB, Roux I, Frydman R, Fanchin R. Serum anti-müllerian hormone levels are negatively related to follicular output RaTe (FORT) in normo-cycling women undergoing controlled ovarian hyperstimulation. *Hum Reprod* (2011) 26:671–7. doi: 10.1093/humrep/deq361